HPV in Men
Genital Warts, Penile/Anal/Oropharyngeal Cancer, and the Case for Male Vaccination (Gardasil 9)
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Gardasil 9 FDA-approved for males and females ages 9-45
Reference only. Not medical advice.
What can go wrong
Most HPV infections are harmless and clear, but persistent high-risk infection can cause penile, anal, and oropharyngeal cancers, often after a long latency. Genital warts, while benign, carry psychological and recurrence burden. The vaccine is very safe; the most common effects are injection-site reactions and, in adolescents, syncope (fainting) shortly after injection, which is why a brief observation period is advised. The vaccine does not treat existing infection or clear established disease, and it does not cover every oncogenic type, so it is not a reason to abandon other prevention.
This is something to take to a clinician. The Atlas can tell you what is known about hpv in men in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Human papillomavirus is the most common sexually transmitted infection; most sexually active people acquire it, and most infections clear without symptoms. Low-risk types (notably HPV 6 and 11) cause anogenital warts; high-risk oncogenic types (notably HPV 16 and 18) cause penile, anal, and oropharyngeal cancers. In men the oropharyngeal cancer link is now especially prominent: HPV-positive oropharyngeal cancer has risen sharply and is more common in men than women. There is no approved routine HPV screening test for men (unlike cervical screening in women), which makes primary prevention central. The 9-valent vaccine (Gardasil 9) is FDA-approved and recommended for males and females; routine vaccination is recommended at ages 11-12, with catch-up through age 26 and shared clinical decision-making for ages 27 to 45.
The most common STI in the world, mostly silent, and a leading driver of throat cancer in men.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
HPV is a non-enveloped DNA virus that infects basal keratinocytes of skin and mucosa through micro-abrasions. Oncogenic types express the E6 and E7 oncoproteins, which inactivate the p53 and retinoblastoma (Rb) tumor-suppressor pathways, driving malignant transformation over years to decades. The vaccines are virus-like particles assembled from the L1 capsid protein; they contain no viral DNA and cannot cause infection, but they induce neutralizing antibodies that prevent the initial infection. Because the vaccine is prophylactic, not therapeutic, it works best before exposure, which is why pre-adolescent vaccination is emphasized.
Why male vaccination matters even without a male screening test
Women benefit from cervical screening that can catch precancer; men have no equivalent routine screening for penile or oropharyngeal HPV disease, so prevention by vaccine is comparatively more important. The ANCHOR trial demonstrated that treating anal high-grade lesions reduces progression to anal cancer in people with HIV, supporting screening in that high-risk group. Vaccinating boys also contributes to herd protection and directly reduces the male-predominant burden of HPV-positive oropharyngeal cancer, which condoms only partially prevent because HPV infects skin not covered by a condom and is transmitted through oral as well as genital contact.
What people get wrong
Often saidHPV is only a women's health issue
ActuallyHPV causes penile and anal cancers and is the main driver of the rising, male-predominant HPV-positive oropharyngeal cancer; men also transmit it and develop genital warts.
Often saidThe HPV vaccine is only for girls
ActuallyGardasil 9 is FDA-approved and recommended for boys and men; routine vaccination at 11-12 with catch-up to age 26 and shared decision-making to 45.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Most common STI
- Yes (globally)
- Wart types
- HPV 6 and 11
- Cancer types
- HPV 16 and 18 (and others)
- Rising male cancer
- HPV-positive oropharyngeal cancer
- Vaccine
- Gardasil 9 (9-valent), ages 9-45
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about HPV in Men. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Giuliano et al., NEJM (quadrivalent vaccine in men)2011
Quadrivalent HPV vaccine prevented external genital lesions and persistent infection in males
Palefsky et al., NEJM (HPV vaccine and anal disease)2011
Vaccine reduced anal intraepithelial neoplasia in MSM
Chaturvedi et al., J Clin Oncol2011
Documented the rising incidence of HPV-positive oropharyngeal cancer, male-predominant
Palefsky et al. (ANCHOR), NEJM2022
Treating anal high-grade squamous intraepithelial lesions reduced progression to anal cancer in people with HIV